Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: the experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party

Bone Marrow Transplantation volume 40, pages 1045–1048 (2007)Cite this article

Abstract

We report the experience of the EBMT Solid Tumours Working Party (STWP) using high-dose chemotherapy (HDCT) with PBPC support in patients with non-small cell lung cancer (NSCLC). Between 1989 and 2004, 36 NSCLC patients (27 men and 9 women), median age 53.5 years (range: 24–62) were treated with 63 HDCT courses. A high-dose carboplatin-based regimen was used in 53% of the cases. Thirty-two patients had relapsed/metastatic disease, while four classified as stage IIIB received HDCT followed by radiotherapy. No treatment-related death occurred. Of 25 patients who were planned to receive multi-cycle HDCT, 4 cases (16%) interrupted the treatment early due to prolonged severe toxicities and 4 (16%) due to progressive disease. Of 36 evaluable patients, 3 (8%) achieved a complete remission and 13 (36%) had a partial remission at an overall response rate of 44%. Of these, one patient with stage IIIB and one with stage IV are alive disease free at 71+ and 149+ months, respectively. After a median follow-up of 48 months (range: 6–149), median survival was 7 months (range: 1–149). Despite one anecdotal case, HDCT did not show significant activity, but induced relevant morbidity in NSCLC patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19–21.

    Article  CAS  Google Scholar 

  2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899–909.

    Article  Google Scholar 

  3. Fischer JR, Manegold C, Bülzebrück H, Vogt-Moykopf I, Drings P . Induction chemotherapy with and without human granulocyte colony-stimulation factor in locally advanced IIIA/IIIB non-small cell lung cancer. Semin Oncol 1994; 3 (Suppl 4): 20–27.

    Google Scholar 

  4. Mori K, Saitoh Y, Tominaga K . Recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for non-small cell lung cancer. Eur J Cancer 1993; 5: 677–685.

    Article  Google Scholar 

  5. Palackdharry CS, Krigel RL . Dose-intensive ifosfamide/carboplatin/etoposide plus granulocyte–macrophage colony-stimulating factor for non-small cell lung cancer. Semin Oncol 1994; 21 (Suppl 4): 6–11.

    CAS  PubMed  Google Scholar 

  6. Kasymjanova G, Kreisman H, Correa JA, Dajczman E, Small D . Does granulocyte colony-stimulating factor affect survival in patients with advanced non-small cell lung cancer? J Thorac Oncol 2006; 1: 564–570.

    Article  Google Scholar 

  7. Rosti G, De Giorgi U, Giovanis P, Cariello A, Dazzi C, Marangolo M . Treatment of small cell lung cancer. Monaldi Arch Chest Dis 1999; 54: 427–434.

    CAS  PubMed  Google Scholar 

  8. Leyvraz S, Perey L, Rosti G, Lange A, Pampallona S, Peters R et al. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999; 17: 3531–3539.

    Article  CAS  Google Scholar 

  9. Ardizzoni A, Tjan-Heijnen VCG, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial—08923. J Clin Oncol 2002; 20: 3947–3955.

    Article  CAS  Google Scholar 

  10. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ, Medical Research Council Lung Cancer Working Party. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized trial. J Clin Oncol 2000; 18: 395–404.

    Article  CAS  Google Scholar 

  11. Basade MM, Gulati SC . High-dose chemotherapy with autologous bone marrow/stem-cell rescue in lung cancer. Lancet 1996; 347: 847–848.

    Article  CAS  Google Scholar 

  12. Gomm SA, Thatcher N, Cutherbert A, Chang J, Burmester H, Hall P et al. High dose combination chemotherapy with ifosfamide, cyclophosphamide, cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small-cell carcinoma of the lung. Br J Cancer 1991; 63: 293–297.

    Article  CAS  Google Scholar 

  13. Shea TC . High-dose carboplatin plus paclitaxel with granulocyte colony-stimulating factor and peripheral blood stem-cell support in non-small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40 (Suppl): 74–78.

    Article  Google Scholar 

  14. Fetscher S . The role of high-dose chemotherapy in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2002; 41: 151–156.

    Article  Google Scholar 

  15. Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H et al. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report. Ann Oncol 1999; 10: 605–607.

    Article  CAS  Google Scholar 

  16. Asmis TR, Ding K, Whitehead M, Seymour L, Shepherd FA, Winton T et al. Are age and comorbidity independent prognostic factors in the treatment of metastatic NSCLC? A review of prospectively randomized National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trials. Proc Am Soc Clin Oncol 2006; 24: 3935, abstract 7117.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto Oncologico Romagnolo-Santa Maria delle Croci Hospital, Ravenna, Italy

    U De Giorgi, M Marangolo & G Rosti

  2. Institut Paoli Calmettes, Marseille, France

    D Blaise, P Viens & A Madroszyk

  3. Centre for Cellular Transplantation, Wroclaw, Poland

    A Lange

  4. Department of Hematology, Sahlgrenska University Hospital, Göteborg, Sweden

    M Brune

  5. Medical University Hospital, St Petersburg, Russia

    B V Afanassiev

  6. Department of Hematology, Ankara University Medical School, Ankara, Turkey

    T Demirer

Authors
  1. U De Giorgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Viens
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Marangolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Madroszyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Brune
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B V Afanassiev
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Rosti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T Demirer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U De Giorgi.

Appendix

Appendix

Institutions participating in this study

U De Giorgi, G Rosti, M Marangolo, Istituto Oncologico Romagnolo—Department of Oncology and Hematology, Santa Maria delle Croci Hospital, Ravenna, Italy; P Viens, A Madroszyk, D Blaise Institut Paoli Calmettes, Marseille, France; A Lange, Centre for Cellular Transplantation, Wroclaw, Poland; M Brune, Sahlgrenska University Hospital, Goeteborg, Sweden; BV Afanassiev, Medical University Hospital, St Petersburg, Russia; T Demirer, Ankara University Medical School, Ankara, Turkey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Giorgi, U., Blaise, D., Lange, A. et al. High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: the experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party. Bone Marrow Transplant 40, 1045–1048 (2007). https://doi.org/10.1038/sj.bmt.1705880

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705880

Keywords

Search

Advanced search

Quick links